Nieuws en video's - GLYCOMIMETICS INC. - Engels - Pagina 2

GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report third quarter financial results on Wednesday, November 9, 2022, at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you will be provided with dial in details. Participants are encouraged to connect 15 minutes in advance of the scheduled start time. A live webcast of the call will be available on the “ Investors ” tab on the GlycoMimetics website. A...

GlycoMimetics, Inc. (the “ Company ”) (NASDAQ:GLYC) today announced that the compensation committee of the Company’s Board of Directors approved the grant on September 2, 2022 of a non-qualified stock option award to purchase an aggregate of 200,000 shares of common stock to Edwin P. Rock, M.D., the Company’s new Senior Vice President and Chief Medical Officer. The award was granted as an inducement equity award outside of the Company’s Amended and Restated 2013 Equity Incentive Plan...

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will present in-person at the H.C. Wainwright 24 th Annual Global Investment Conference in New York, NY on Wednesday, September 14, 2022 at 3:00 p.m. ET. An archived recording of the presentation will be available for 90 days on the GlycoMimetics website at https://ir.glycomimetics.com/investor-relations . About GlycoMimetics, Inc. GlycoMimetics is a clinical-stage biotechnology company discovering...

GlycoMimetics, Inc. (Nasdaq: GLYC), a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that Edwin Rock, M.D., Ph.D. has joined the executive leadership team as Chief Medical Officer (CMO). Dr. Rock brings nearly two decades of biopharmaceutical clinical development experience, most recently serving as CMO for Partner Therapeutics, a privately-held commercial stage biotech based in Massachusetts....

GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results and highlights for the second quarter ended June 30, 2022. Cash and cash equivalents as of the end of the quarter were $60.2 million. “During second quarter, we made strides in advancing our transformation from a research company to a commercially focused organization and are encouraged by the continued progress of our pivotal Phase 3 trial of uproleselan in relapsed/refractory AML,” said Harout Semerjian, Chief...

GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report second quarter financial results on Wednesday, August 3, 2022, at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you will be provided with dial in details. Participants are encouraged to connect 15 minutes in advance of the scheduled start time. A live webcast of the call will be available on the “ Investors ” tab on the GlycoMimetics website. A...

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that the Company will participate at the Jefferies 2022 Healthcare Conference, on June 8 th , in New York, NY. Chief Executive Officer Harout Semerjian and Chief Financial Officer Brian Hahn will attend in person. Research Analyst Roger Song, M.D. will host a fireside chat with Mr. Semerjian. An archived recording of the chat will be available for thirty days on the GlycoMimetics website at https://ir.glycomimetics.com/investor-relations ,...

GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results and highlights for the first quarter ended March 31, 2022. Cash and cash equivalents at March 31, 2022 were $76.5 million. “During the first quarter, we advanced our transformation from a research company to a commercially-focused organization. Our clinical team continues to collect and confirm data and track events in real time from our Phase 3 trial in the relapsed/refractory patient population. Based on current...

GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that it will host a conference call and webcast to report first quarter financial results on Thursday, April 28, 2022, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants or (216) 562-0466 for international participants, with participant code 1068226. Participants are encouraged to connect 15 minutes in advance of the call to ensure that all callers are able to connect. A webcast replay will...

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that the Company will participate at the 34 th Annual Roth Conference in Laguna Niguel, California, March 14 and 15. Chief Executive Officer Harout Semerjian and Chief Financial Officer Brian Hahn will attend in person. Research Analyst Zegbeh Jallah, Ph.D. will host a fireside chat with Mr. Semerjian. An archived recording of the chat will be available for thirty days on the GlycoMimetics website at...

GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that the compensation committee of the Company’s Board of Directors approved the grant on March 1, 2022 of a non-qualified stock option award to purchase an aggregate of 100,000 shares to Deepak Tiwari, the Company’s new Vice President, Technical Operations. The award was granted as an inducement equity award outside of the Company’s 2013 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4), and was...

GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results and highlights for the fourth quarter and year ended December 31, 2021. Cash and cash equivalents at December 31, 2021 were $90.3 million. “During 2021, we focused on completing enrollment of our pivotal trial evaluating uproleselan in AML. Towards the end of the year, within two weeks of each other, GlycoMimetics completed enrollment of our Phase 3 trial and the NCI completed enrollment of the Phase 2 portion of its Phase...

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Dr. Deepak Tiwari has joined the Company as Vice President, Technical Operations. “Dr. Tiwari brings over 25 years of diverse CMC experience. He has contributed to more than 30 regulatory submissions and 15 commercial product launches throughout his career. As we continue to move uproleselan forward, Deepak’s breadth of experience and leadership is a valuable addition to GlycoMimetics,” commented Harout Semerjian, GlycoMimetics’...

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its fourth quarter and 2021 year-end financial results on Thursday, March 3, 2022, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants and (216) 562-0466 for international participants, with participant code 4048456. Participants are encouraged to connect 15 minutes in advance of the call to ensure they can connect. A webcast replay will...

GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that the compensation committee of the Company’s Board of Directors approved the grant on February 16, 2022 of a non-qualified stock option award to purchase an aggregate of 235,000 shares to Bruce Johnson, the Company’s new Senior Vice President and Chief Commercial Officer. The award was granted as an inducement equity award outside of the Company’s 2013 Equity Incentive Plan in accordance with NASDAQ Listing Rule...

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Bruce Johnson has joined its executive leadership team as Senior Vice President and Chief Commercial Officer. “Bruce brings to GlycoMimetics a wealth of oncology / hematology expertise particularly in leading commercial and development activities across multiple launches. He shepherded two AML drugs, Midostaurin and Venetoclax, through late-stage development and approval, uniquely qualifying him to lead the commercialization efforts of...

GlycoMimetics, Inc. (Nasdaq: GLYC) this week at the 63 rd American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta presented two posters providing support for targeting both CXCR4 and E-selectin with GMI-1359, the Company’s dual antagonist of CXCR4 and E-selectin, as a novel treatment strategy for patients with AML. “Both posters demonstrate the potential value of blocking extrinsic factors of AML drug resistance in the bone marrow microenvironment with our dual-function...

GlycoMimetics, Inc. (Nasdaq: GLYC), a clinical-stage biotechnology company, announced today that the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and the Alliance for Clinical Trials in Oncology, have completed enrollment of 267 patients in the Phase 2 portion of the adaptive Phase 2/3 trial evaluating whether uproleselan improves overall survival in newly diagnosed patients 60 years or older with acute myeloid leukemia (AML). The randomized, controlled trial...

GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that the compensation committee of the Company’s Board of Directors approved the grant on November 22, 2021 of a non-qualified stock option award to purchase an aggregate of 100,000 shares to one new employee. The award was granted as an inducement equity award outside of the Company’s 2013 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4), and was made as an inducement material to the acceptance of...

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Apollomics has dosed the first patient in China in a Phase 3 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML). Apollomics’ Phase 3 trial with APL-106 is part of the overall development program for Apollomics in China that also includes an ongoing Phase 1 pharmacokinetics (PK) and tolerability study. The Phase 3 clinical trial is part of a randomized,...